NCT04466566View on ClinicalTrials.gov

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy
Interventions
OTHER

Saline

Saline will serve as the control

BIOLOGICAL

Exendin-9,39

Exendin-9,39 will block the GLP-1 receptor

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Adrian Vella

OTHER